Structure Therapeutics Inc. financial data

Symbol
GPCR on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2054% % -26%
Debt-to-equity 5.6% % 35%
Return On Equity -15% % 7.6%
Return On Assets -14% % 8.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 212,525,437 shares 23%
Common Stock, Shares, Outstanding 212,513,000 shares 24%
Entity Public Float $834,900,000 USD -57%
Common Stock, Value, Issued $21,000 USD 24%
Weighted Average Number of Shares Outstanding, Basic 177,596,000 shares 12%
Weighted Average Number of Shares Outstanding, Diluted 175,469,000 shares 2.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $225,255,000 USD 107%
General and Administrative Expense $61,554,000 USD 25%
Operating Income (Loss) $176,560,000 USD -12%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $140,687,000 USD -15%
Income Tax Expense (Benefit) $515,000 USD 66%
Net Income (Loss) Attributable to Parent $141,202,000 USD -15%
Earnings Per Share, Basic -0.8 USD/shares -2.6%
Earnings Per Share, Diluted -0.37 USD/shares -85%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $799,623,000 USD 372%
Cash, Cash Equivalents, and Short-term Investments $1,446,200,000 USD 64%
Assets, Current $1,570,303,000 USD 76%
Property, Plant and Equipment, Net $6,653,000 USD 91%
Operating Lease, Right-of-Use Asset $6,245,000 USD 77%
Other Assets, Noncurrent $717,000 USD -86%
Assets $1,583,918,000 USD 75%
Accounts Payable, Current $13,864,000 USD 73%
Employee-related Liabilities, Current $12,434,000 USD 71%
Liabilities, Current $63,285,000 USD 76%
Operating Lease, Liability, Noncurrent $3,609,000 USD 67%
Other Liabilities, Noncurrent $647,000 USD 114%
Liabilities $67,541,000 USD 75%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,054,000 USD 15%
Retained Earnings (Accumulated Deficit) $470,300,000 USD -43%
Stockholders' Equity Attributable to Parent $1,516,377,000 USD 75%
Liabilities and Equity $1,583,918,000 USD 75%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $52,229,000 USD -53%
Net Cash Provided by (Used in) Financing Activities $809,000 USD 15%
Net Cash Provided by (Used in) Investing Activities $34,033,000 USD 2300%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 212,513,000 shares 24%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $17,387,000 USD 46%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $799,623,000 USD 372%
Deferred Tax Assets, Valuation Allowance $106,954,000 USD 57%
Deferred Tax Assets, Gross $108,339,000 USD 57%
Operating Lease, Liability $6,487,000 USD 68%
Depreciation $274,000 USD 23%
Payments to Acquire Property, Plant, and Equipment $314,000 USD 94%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $141,062,000 USD -15%
Lessee, Operating Lease, Liability, to be Paid $7,196,000 USD 72%
Property, Plant and Equipment, Gross $9,622,000 USD 88%
Operating Lease, Liability, Current $2,878,000 USD 69%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,726,000 USD -8.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,253,000 USD 69%
Operating Lease, Weighted Average Discount Rate, Percent 0.077 pure 1.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $709,000 USD 117%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,279,000 USD 236%
Deferred Tax Assets, Operating Loss Carryforwards $55,310,000 USD 111%
Preferred Stock, Shares Authorized 100,000,000 shares 0%
Unrecognized Tax Benefits $9,497,000 USD 20%
Lessee, Operating Lease, Liability, to be Paid, Year Four $938,000 USD
Operating Lease, Payments $600,000 USD 100%
Additional Paid in Capital $1,985,602,000 USD 66%
Deferred Tax Assets, Net of Valuation Allowance $913,000 USD -25%
Share-based Payment Arrangement, Expense $28,991,000 USD 54%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%